A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients

Transplantation

Volumn 67, Issue 3, 1999, Pages 411-415

  Shapiro, Ron ^a   Jordan, Mark L ^a   Scantlebury, Velma P ^a   Vivas, Carlos ^a   Marsh, J Wallis ^a   McCauley, Jerry ^b   Johnston, James ^b   Randhawa, Parmjeet ^a   Irish, William ^a   Gritsch, H Albin ^a   Naraghi, Robert ^a   Hakala, Thomas R ^a   Fung, John J ^a   Starzl, Thomas E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CYTOMEGALOVIRUS; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECIPIENT;

EID: 0033557356     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199902150-00012     Document Type: Article

References (35)

1. Starzl TE, Fung JJ, Jordan M, et al. Kidney transplantation under FK506. JAMA 1990; 264: 63.
2. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of FK506-based immunosuppression after renal transplantation Transplantation 1995; 59: 485.
3. Shapiro R, Jordan ML, Scantlebury VP, et al. The superiority of tacrolimus in renal transplant recipients: the Pittsburgh experience. In: Terasaki PI, Cecka JM (eds). Clinical transplants 1995. Los Angeles: UCLA Tissue Typing Laboratory, 1996: 199.
4. Shapiro R. Tacrolimus (FK-506) in kidney transplantation. Transplant Proc 1997; 29: 45.
5. Gjertson DW, Cecka JM, Terasaki PI. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation 1995; 60: 1384.
6. Ochiai T, Ishibashi M, Fukao K, et al., for the Japanese FK506 Study Group. Japanese multicenter studies of FK506 in renal transplantation. Transplant Proc 1995; 22 (1): 50.
7. Japanese FK506 Study Group, Ochiai K, Fukao K, et al. Phase III study of FK506 in kidney transplantation. Transplant Proc 1995; 22: 829.
8. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977.
9. Miller J, Pirsch JD, Deierhoi MH. FK506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. Transplant Proc 1997; 29: 304.
10. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64 (3): 436.
11. Shapiro R, Jordan ML, Scantlebury VP, et al. Tacrolimus in renal transplantation. Transplant Proc 1996; 28 (4): 2117.
12. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
13. Sollinger HW for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
14. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
15. Halloran P, Mathew T, Tomlanovich S, et al., for the International Mycophenolate Mofetil Renal Transplant Study Groups. Mycophenolate mofetil in renal allograft recipients. Transplantation 1997; 63 (1): 39.
16. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/ prednisone/mycophenolate mofetil in cadaveric renal transplantation: first report. J Urol, in press.
17. Czer L, Jordan SC, Tyan D, et al. Novel approach to treatment of patients with cytotoxic antibodies after heart transplantation: use of IVIG. Circulation 1989; 88: 494.
18. Toyoda M, Zhand XM, Pertosian A, Wachs K, Moudgil A, Jordan SC. Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma globulin. Transplant Immunol 1994; 2: 337.
19. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. Mosby Year Book 1985; 51.
20. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Statistical Assoc 1958; 53: 457.
21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163.
22. Jordan ML, Novick AC, Steinmuller D, et al. Renal transplantation in the older recipient. J Urol 1985; 134: 243.
23. Roza AM, Leptk SG, Johnson CP, Adams MB. Renal transplantation in patients more than 65 years old. Transplantation 1989; 48: 689.
24. Murie JA, Lauffer G, Gray D, et al. Renal transplantation in the older patient. Transplant Proc 1989; 21: 2024.
25. Vivas CA, Hickey DP, Jordan ML, et al. Renal transplantation in patients 65 years or older. J Urol 1992; 147: 990.
26. Cecka JM, Terasaki PI. The UNOS Scientific Renal Transplant Registry. In: Terasaki PI, Cecka JM (eds). Clinical transplants 1993. Los Angeles: UCLA Tissue Typing Laboratory, 1994; 1.
27. Lim EC, Terasaki PI. Early graft function. In: Terasaki PI, Cecka JM (eds). Clinical transplants 1991. Los Angeles: UCLA Tissue Typing Laboratory, 1992; 401.
28. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of FK506/prednisone vs. F506/azathioprine/ prednisone in renal transplant patients. Transplant Proc 1995; 27 (1): 814.
29. Filo RS and the FK506 Kidney Transplant Study Group. Tacrolimus in kidney transplantation: two-year results of the US, randomized comparative, phase III study. 16th Annual Meeting of the American Society of Transplant Physicians, Chicago, IL, May, 1997.
30. Zucker K, Rosen A, Tsaroucha A, et al. Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy. Transplant Proc 1997; 29 (1-2): 334.
31. Roth D, Colona J, Burke GW, Ciancio G, Esquenazi V, Miller J. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Transplantation 1998; 65 (2): 248.
32. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338 (3): 161.
33. Kirkman RL, Vincenti F, Pescovitz GL, et al. A phase I/II randomized, double blind, placebo-controlled study of Zenapax in combination with CellCept, Neoral and steroids. 16th Annual Meeting of the American Society of Transplant Physicians, Chicago, IL, May, 1997.
34. ™). 23rd Annual Scientific Meeting of the American Society of Transplant Surgeons, May, 1997.
35. Nashan B, Moore R, Amlot P, et al. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group [published erratum appears in Lancet 1997 Nov 15;350(9089):1484]. Lancet 1997; 350: 1193.